Aspirin in Asymmetrically Intrauterine Growth
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03038607|
Recruitment Status : Completed
First Posted : January 31, 2017
Last Update Posted : January 31, 2017
Intrauterine growth restriction refers to a fetus that has failed to get a specific measures by a gestational age. Asymmetric type of Intrauterine growth restriction is known by normal sized head with smaller abdomen.It is important to recognize the growth restricted fetuses, because these fetuses may have fetal or neonatal complications.
When blood flow is increased, the oxygen and nutrients will deliver good to the fetus. The role of low-dose aspirin therapy in management of intrauterine growth restriction is controversial. It has been used, in many studies, in prevention of intrauterine growth restriction especially in women at high risk of pre-eclampsia or obstetrical antiphospholipid syndrome.
|Condition or disease||Intervention/treatment||Phase|
|Intrauterine Growth Restriction Asymmetrical||Drug: Aspirin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Low-dose Aspirin on Fetal Weight of Idiopathic Asymmetrically Intrauterine Growth Restricted Fetuses With Abnormal Umbilical Doppler Indices|
|Actual Study Start Date :||January 2016|
|Actual Primary Completion Date :||January 2017|
|Actual Study Completion Date :||January 2017|
|Active Comparator: Aspirin group||
This group were subjected to aspirin 75 mg once daily for 6 weeks.
|No Intervention: No intervention|
- Estimated fetal weight [ Time Frame: 6 weeks ]
- Birth weight [ Time Frame: 6 weeks ]
- Changes in Doppler blood flow indices in umbilical artery [ Time Frame: 6 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03038607
|Women Health Hospital - Assiut university|
|Assiut, Egypt, 71111|